CytoSorbents Provides Update on ISICEM 2013 Critical Care Conference
CytoSorbents Corporation (CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, provides an update on its recent exhibition at the 33rdInternational Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium last week. This year, approximately 6,000 participants from all over the world attended for an up-to-date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill.
At its newly re-designed booth (see picture inset), CytoSorbents featured its flagship product, CytoSorb(R), the only specifically approved cytokine blood filter in the European Union. The goal of CytoSorb(R) is to prevent or treat organ failure - the cause of nearly half of all deaths in the ICU - by controlling "cytokine storm" and reducing deadly inflammation. CytoSorb(R) has now been used in many different critical care applications, and is generating revenue through direct sales in primarily Germany and Austria, where reimbursement exists. It is also approved for sale throughout all 27 European Union countries, and can be sold, with proper registration, in many other countries outside the E.U.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, "This ISICEM symposium was one of our most productive conferences we have had to date and we were pleased with the new and ongoing interest in CytoSorb(R). Our mindshare amongst clinicians has clearly increased since last year's conference and our booth traffic was very steady, with potential new customers and existing key opinion leaders who are collaborating with us on additional clinical studies. During our time in Brussels, we advanced our discussions with distributors from many major countries as well as potential strategic corporate partners.
real potential to revolutionize critical care therapy."
*Namas, RA, et al., "Hemoadsorption reprograms inflammation in experimental gram-negative septic peritonitis: Insights from in vivo and in silico studies" Molecular Medicine, 2012, vol. 18, p. 1366-1374.
Significant Interest Generated from Distributors and Key Opinion Leaders